Corpus overview


Overview

MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus


Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Identification of pulmonary comorbid diseases network based repurposing effective drugs for COVID-19 MESHD

    Authors: Jai Chand Patel; Rajkumar Tulswani; Pankaj Khurana; Yogendra Kumar Sharma; Lilly Ganju; Bhuvnesh Kumar; Ragumani Sugadev

    doi:10.21203/rs.3.rs-28148/v1 Date: 2020-05-08 Source: ResearchSquare

    The number of hospitalization of COVID-19 MESHD patients with one or more comorbid diseases is highly alarming. Despite the lack of large clinical data and incomplete understanding of virus pathology, identification of the COVID-19 MESHD associated diseases with clinical precision are highly limited. In this regard, our text mining of 6238 PubMed abstracts (as on 23 April 2020) successfully identified broad spectrum of COVID-19 MESHD comorbid diseases/disorders (54), and their prevalence SERO on the basis of the number of occurrence of disease terms in the abstracts. The disease ontology based semantic similarity network analysis revealed the six highly comorbid diseases of COVID-19 MESHD namely Viral Pneumonia HP, Pulmonary Fibrosis HP Pulmonary Fibrosis MESHD, Pulmonary Edema HP Pulmonary Edema MESHD, Acute Respiratory Distress Syndrome MESHD Respiratory Distress HP Syndrome ( ARDS MESHD), Chronic Obstructive Pulmonary Disease HP Chronic Obstructive Pulmonary Disease MESHD ( COPD MESHD) and Asthma HP. The disease gene bipartite network revealed 15 genes that were strongly associated with several viral pathways including the corona viruses may involve in the manifestation (mild to critical) of COVID-19 MESHD. Our tripartite network- based repurposing of the approved drugs in the world market revealed six promising drugs namely resveratrol, dexamethasone, acetyl cysteine, Tretinoin, simvastatin and aspirin to treat comorbid symptoms of COVID-19 MESHD patients. Our animal studies in rats and literatures strongly supported that resveratrol is the most promising drug to possibly reduce several comorbid symptoms associated with COVID-19 MESHD including the severe hypoxemia HP hypoxemia MESHD induced vascular leakage. Overall, the anti-viral properties of resveratrol against corona virus could be readily exploited to effectively control the viral load at early stage of COVID-19 MESHD infection through nasal administration.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.